Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Gilead Sciences    GILD

GILEAD SCIENCES (GILD)
My previous session
Most popular
  Report  
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsofficial PublicationsSector newsTweets

Gilead Sciences : buys US firm Kite Pharma for $11.9bn

share with twitter share with LinkedIn share with facebook
share via e-mail
0
10/05/2017 | 12:14pm CEST

Biopharmaceutical company Gilead Sciences has completed the acquisition of US-based Kite Pharma for approximately $11.9bn.

Kite Pharma specialises in the development of new cell therapies, which use a patients own immune cells to fight cancer.

Gilead Sciences has completed the transaction through Dodgers Merger Sub, a wholly owned subsidiary of the company.

On 28 August, the two companies entered a definitive merger agreement to complete the acquisition.

A tender offer was started on 5 September to buy all the outstanding shares of Kite Pharma at a price of $180 each.

Gilead Sciences has successfully concluded the tender offer for all of Kite Pharma`s common stock shares.

"Kite Pharma has become a wholly owned subsidiary of Gilead Sciences."

Gilead Sciences president and chief executive officer Dr John F Milligan said: Throughout our respective histories, each company has demonstrated a deep commitment to advancing life-saving therapies for people who need them."

With the completion of the acquisition, Kite Pharma has become a wholly owned subsidiary of Gilead Sciences.

Bank of America Merrill Lynch, Lazard and Barclays acted as financial advisors to Gilead Sciences, while Skadden, Arps, Slate, Meagher and Flom served as the companys legal advisors.

Kite Pharma has developed engineered cell therapies that express either a chimeric antigen receptor (CAR) or an engineered T-cell receptor (TCR), based on the form of cancer.

The companys major CAR T therapy candidate, axicabtagene ciloleucel (axi-cel), is expected to be the first available treatment for refractory aggressive non-Hodgkin lymphoma, including diffuse large B-cell lymphoma (DLBCL), transformed follicular lymphoma (TFL), and primary mediastinal B-cell lymphoma (PMBCL).

(c) APS 2017. All Rights Reserved Provided by SyndiGate Media Inc. (Syndigate.info)., source Middle East & North African Newspapers

Stocks mentioned in the article
ChangeLast1st jan.
GILEAD SCIENCES -3.53% 72.92 Delayed Quote.5.51%
KITE PHARMA INC 0.00%-End-of-day quote.300.96%
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on GILEAD SCIENCES
08/17Bach proposes CAR T payment options for CMS
AQ
08/16GILEAD SCIENCES : Patent Issued for Use Of Solid Carrier Particles To Improve Th..
AQ
08/16GILEAD SCIENCES : "Polycyclic-Carbamoylpyridone Compounds And Their Pharmaceutic..
AQ
08/16GILEAD SCIENCES' : Trademark Application for "GILEAD HIVAGE POSITIVELY" Filed
AQ
08/16GILEAD SCIENCES : Report Summarizes Amino Acids Study Findings from Gilead Scien..
AQ
08/14GILEAD SCIENCES : Announces Executive Promotions
BU
08/10GILEAD SCIENCES : China National Drug Administration Approves Gilead's Genvoya, ..
AQ
08/09GILEAD SCIENCES : An Application for the Trademark "EMTAUGRIS" Has Been Filed by..
AQ
08/09GILEAD SCIENCES : An Application for the Trademark "RYMTACLI" Has Been Filed by ..
AQ
08/09GILEAD SCIENCES : Trademark Application for "OMPLIXIS" Filed by Gilead Sciences
AQ
More news
News from SeekingAlpha
08/17Gilead continues selloff, down 3% 
08/16A Synopsis Of The HIV Market 
08/16PEPSICO AND GILEAD : 2 Very Different CEO Departures 
08/15Investors shun healthcare stocks in broad market selloff 
08/14ONE YEAR LATER : Lessons Learned In CAR-T 
Financials ($)
Sales 2018 21 360 M
EBIT 2018 11 160 M
Net income 2018 6 650 M
Debt 2018 12 363 M
Yield 2018 3,01%
P/E ratio 2018 14,71
P/E ratio 2019 13,72
EV / Sales 2018 5,12x
EV / Sales 2019 5,07x
Capitalization 97 018 M
Chart GILEAD SCIENCES
Duration : Period :
Gilead Sciences Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends GILEAD SCIENCES
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 27
Average target price 87,9 $
Spread / Average Target 16%
EPS Revisions
Managers
NameTitle
John F. Milligan President, Chief Executive Officer & Director
John C. Martin Chairman
Robin L. Washington CFO, Principal Accounting Officer & Executive VP
Andrew Cheng Chief Medical Officer & Executive Vice President
John G. McHutchison Chief Scientific Officer
Sector and Competitors
1st jan.Capitalization (M$)
GILEAD SCIENCES5.51%100 220
VERTEX PHARMACEUTICALS16.75%44 961
REGENERON PHARMACEUTICALS-1.11%38 873
NEUROCRINE BIOSCIENCES, INC.46.41%10 514
GENMAB2.24%9 810
BLUEBIRD BIO INC-12.30%8 449